R&D at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s R&D?
- Taysha Gene Therapies, Inc. (TSHA) reported R&D of $33.81M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s R&D changed year-over-year?
- Taysha Gene Therapies, Inc.'s R&D increased by 117.2% year-over-year, from $15.57M to $33.81M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s R&D?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s R&D has grown at a -10.0% compound annual growth rate (CAGR), from $131.94M to $86.4M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.